BREAKING NEWS America gets another Alzheimer's drug in its arsenal: FDA approves Eli Lilly's treatment which slows symptoms down READ MORE: 'Miracle' Alzheimer's drugs could be shrinking brains of patients By Alexa Lardieri U.S. Deputy Health Editor Dailymail.
Com Published: 19:11 BST, 2 July 2024 | Updated: 19:37 BST, 2 July 2024 e-mail 4 View comments The US FDA has approved donanemab, a treatment for Alzheimer's disease that helps the body remove the hallmark plaque that builds up in the brain and causes dementia. Made by Indianapolis-based Eli Lilly, donanemab is a monoclonal antibody treatment designed to slow the progression of early signs of Alzheimer's and clinical trials have shown the treatment slowed cognitive decline in patients by up to 35 percent. Now approved, Eli Lilly said it will be sold under the name Kisunla to be administered by once-monthly IV infusions.
It will cost $695 per vial - amounting to about $32,000 a year. While a breakthrough in Alzheimer's care, experts have raised concerns about donanemab due to known risks of brain bleeds, which killed several trial patients. Made by Indianapolis-based Eli Lilly, donanemab is a monoclonal antibody treatment designed to slow the progression of early signs of Alzheimer's disease Donanemab will be sold under the name Kisunla and will cost $695 per vial - amounting to about $32,000 a year Dr Howard Fillit, co-Founder and chief science officer at the Alzheimer's Drug Discovery Foundation (ADDF), said in a press .